Sublingual minoxidil is sold as the smooth-release, safer alternative to standard oral. The published pharmacokinetics say it is neither: at 5 mg it has the same peak timing as standard oral and roughly 3x the peak of MINX at the same dose. Here are the three PK tests a real prolonged-release oral minoxidil has to pass — and where each route actually lands.
This is the post no one in hair wants to write, because everyone wants to sell you standard oral minoxidil with a fancy upcharge. The published pharmacokinetics tell a single story: sublingual at 5 mg has the same peak timing as standard oral and a peak about 3x higher than MINX at the same dose. Only one of these routes meets the bar for prolonged release.
Sublingual minoxidil is sold as the smooth-release, safer alternative to standard oral minoxidil. The published pharmacokinetics say it is neither. At 5 mg, the projected sublingual peak shows up at the same time as standard oral's peak, at roughly half the height. Same fast-on, fast-off curve. Same Tmax window. The "smoother" framing has become a marketing convenience, not a pharmacokinetic finding.
At the same time, telehealth services are pitching standard oral minoxidil with instructions to put the tablet under the tongue. Standard oral tablets are formulated for stomach disintegration, not mucosal absorption. Held under the tongue, they take 10 to 30 minutes to dissolve at the outside, by which time most patients have already swallowed saliva and the dose has effectively gone through the normal GI route. That is not sublingual delivery. That is delayed oral with a worse taste experience.
This post lays out the three pharmacokinetic tests a real prolonged-release oral minoxidil has to pass, walks through the published sublingual data against those tests, and shows where MINX (Anagen's lipid-matrix oral minoxidil capsule) actually sits.
Smooth release is a claim about when the peak shows up. If the peak shows up at the same time as standard immediate-release oral, you do not have smooth release. You have low-magnitude immediate release.
| Route | Dose | Tmax | Source |
|---|---|---|---|
| Standard IR oral | 5 mg | ~23 min | Fleishaker 1989 (n=29, measured) |
| Sublingual | 0.45 mg | ~30 min | Bokhari 2022 (n=20 active, measured) |
| Sublingual | 5 mg | not reported | Sanabria 2025 efficacy trial (no PK measured) |
| MINX (fed, modeled) | 5 mg | ~9 to 10 h | Bakst 2026, two-subject pilot |
Sublingual and IR oral peak at essentially the same time. The shape of the two curves is identical. MINX is the only route that meaningfully moves the peak from minutes to hours.
The Sanabria 2025 sublingual-vs-oral head-to-head trial used 5 mg sublingual and did not measure plasma minoxidil at all. The paper itself lists the absence of blood pressure and heart rate monitoring as a limitation. The only published sublingual PK number in the literature is Bokhari 2022 at 0.45 mg = 1.62 ng/mL Cmax at 30 minutes post-dose. That is the entire dataset.
Linear PK scaling is defensible because Fleishaker 1989 showed standard oral minoxidil is dose-proportional from 2.5 to 10 mg. Applying linear scaling to Bokhari 2022's measured 0.45 mg Cmax of 1.62 ng/mL puts 5 mg sublingual at about 18 ng/mL. (Math: 5 / 0.45 × 1.62 = 18.0 ng/mL.)
| Route at 5 mg | Cmax | vs 21.7 ng/mL cardiac threshold | vs MINX |
|---|---|---|---|
| Standard IR oral (measured) | ~37 ng/mL | ~70% above threshold (transient) | ~5.7x higher |
| Sublingual (projected, linear) | ~18 ng/mL | ~17% below threshold (tight) | ~3x higher |
| MINX (modeled, fed) | ~6.5 ng/mL | ~70% below threshold (wide) | reference |
The 5 mg sublingual Cmax is projected, not measured. It assumes linear PK scaling from a single published 0.45 mg data point. Bokhari 2022 reported individual variability of 0.3 to 5.3 ng/mL at 0.45 mg; scaled up, the upper tail at 5 mg could approach or exceed the cardiac threshold on individual doses.
Sublingual at 5 mg has a peak that is real, IR-shaped, and roughly 3x the peak of MINX at the same total daily dose. That is not what a prolonged-release product looks like. That is a slightly muted standard oral curve.
For a route to qualify as smooth release (as opposed to "lower dose of immediate release"), it has to demonstrate three things in measured human pharmacokinetic data.
| Criterion | Standard IR oral 5 mg | Sublingual 5 mg | MINX 5 mg (fed) |
|---|---|---|---|
| A very delayed peak (Tmax in hours, not minutes) | No (~23 min) | No (~30 min, projected) | Yes (~9 to 10 h, modeled) |
| A very low peak (below the cardiac threshold by a wide margin) | No (~37 ng/mL, above threshold) | Marginal (~18 ng/mL, ~17% below, projected) | Yes (~6.5 ng/mL, ~70% below, modeled) |
| The same area under the curve as a standard dose | Reference (AUC∞ ~55 ng·h/mL) | Not reported at 5 mg in published trials | Modeled equivalent (AUC∞ ~60 ng·h/mL, range 53 to 81, two-subject pilot) |
| Score | 0 of 3 | 0 of 3 (1 marginal) | 3 of 3 |
The Sanabria 2025 sublingual head-to-head trial did not measure plasma minoxidil, so the 5 mg sublingual row uses linear projection from Bokhari 2022. MINX numbers are modeled from a two-subject pilot with a measured 0 to 8 hour sampling window; the formal bioanalytical PK study at Sannova is underway.
The only published head-to-head of sublingual vs standard oral minoxidil is Sanabria 2025, a 24-week double-blind RCT in Brazilian men with androgenetic alopecia, published as a Letter to the Editor in JEADV.
Design. Single center, Brazil. Men with Norwood-Hamilton 3V, 4V, or 5V pattern. 110 enrolled, 85 completed (23% dropout, not characterized). Sublingual arm received a compounded 5 mg sublingual product from Farmatec Pharmacy in Porto Alegre, plus oral placebo. Oral arm received 5 mg oral plus sublingual placebo. The paper itself lists "absence of blood pressure and heart rate monitoring" as a limitation. Plasma minoxidil was not measured.
| Endpoint | Sublingual 5 mg | Oral 5 mg | p-value |
|---|---|---|---|
| Vertex total hair density (change) | +24.5 hairs/cm² | +21.8 hairs/cm² | 0.850, not different |
| Non-vellus density (change) | +7.8 hairs/cm² | +7.4 hairs/cm² | 0.577, not different |
| Blind-rated clinical improvement | 42% | 40% | 0.69, not different |
| Palpitations (patient-reported) | 0% (0 of 43) | 9.3% (4 of 42) | 0.048 |
| Upper-back hypertrichosis | 43.8% | 18.6% | 0.010, sublingual higher |
The paper's own conclusion: "SM 5 mg per day did not demonstrate superiority over OM 5 mg per day in the treatment of male AGA after 24 weeks."
On hair growth, the two routes were a wash. Total density p = 0.850. Non-vellus density p = 0.577. Blind-rated improvement p = 0.69. The paper does not claim superiority.
On palpitations, sublingual was significantly lower. 0% vs 9.3%, p = 0.048. This is the strongest result in the paper. It is also patient-reported, in a trial that explicitly did not monitor blood pressure or heart rate. The mechanism is asserted, not measured.
On upper-back hypertrichosis, sublingual was significantly higher. 43.8% vs 18.6%, p = 0.010. The AE profile differs between routes, not uniformly in sublingual's favor.
Conflict of interest. Senior author Rodney Sinclair discloses four sublingual minoxidil patents (US10226462, US16344288, US201990269684, US162522107) and stock ownership in Samson Clinical Pty Ltd, the company developing the sublingual lozenge. The COI is openly disclosed in the paper.
This is the part that has gotten the least scrutiny. Telehealth services are now pitching standard oral minoxidil with instructions to put the tablet under the tongue. The pitch is that the patient gets "sublingual delivery" from a standard oral SKU. The pitch is wrong, and the reason is formulation, not pharmacology.
Standard oral minoxidil tablets are designed for gastric disintegration. Croscarmellose or starch glycolate disintegrants activate in stomach acid and mechanical churning, not in 1 to 2 mL of static saliva under the tongue. PVP or hypromellose binders resist rapid breakdown. Magnesium stearate is hydrophobic. Some tablets have a film coat that further slows dissolution. There are no sweeteners or flavor agents, and minoxidil is bitter.
| Dosage form | Time to fully dissolve under the tongue |
|---|---|
| Standard oral tablet (the telehealth "put it under your tongue" pitch) | 10 to 30 minutes, MAX |
| Sinclair-style sublingual lozenge or troche (503A compounded) | 1 to 5 minutes |
| Rapidly disintegrating sublingual tablet | under 60 seconds |
For sublingual to actually work as a smooth-release product, the tablet would need to dissolve for hours, not minutes. None of these dosage forms does that.
Held under the tongue, a standard oral tablet takes 10 to 30 minutes to fully dissolve at the outside. Most patients swallow saliva within the first 1 to 3 minutes, well before the tablet has meaningfully broken down. The fraction that absorbs through the oral mucosa is small. The rest gets swallowed and goes through the normal oral GI route, hitting hepatic first-pass metabolism anyway.
The "put it under your tongue" pitch is delayed oral, not sublingual delivery. It does not change the PK shape. It just changes the timing of when the patient swallows.
MINX is Anagen's 503A compounded lipid-matrix prolonged-release oral minoxidil capsule (Bakst 2026, two-subject pilot). It uses a Compritol 888 ATO matrix to slow drug release across the GI tract.
Against the three prolonged-release criteria above:
| Criterion | MINX (5 mg, fed, modeled) | Pass? |
|---|---|---|
| A very delayed peak (Tmax in hours, not minutes) | Tmax ~9 to 10 h | Yes |
| A very low peak (below the cardiac threshold by a wide margin) | Cmax ~6.5 ng/mL (~70% below 21.7 ng/mL) | Yes |
| The same area under the curve as a standard dose | AUC∞ ~60 ng·h/mL (range 53 to 81), comparable to IR's 55 ng·h/mL | Yes |
| Overall | 3 of 3 | Yes |
MINX PK numbers are modeled from a two-subject pilot, with a measured 0 to 8 hour sampling window. The formal bioanalytical PK study at Sannova is underway and will provide the larger-N measured replication.
The follicular pharmacology behind why curve shape matters: minoxidil is a prodrug. The follicular enzyme SULT1A1 converts it to minoxidil sulfate (Buhl 1990), which is ~14 times more potent than the parent at the follicle. Roberts 2014, in a female AGA cohort, found that follicular SULT1A1 activity predicts topical minoxidil response with about 93% sensitivity and 83% specificity. The enzyme is rate-limited. Once it is saturated, more substrate does not make more product.
A standard 5 mg oral dose floods the follicular enzyme in the first hour. By hour 6, plasma minoxidil is back near baseline. The enzyme is slammed, then starved. The hypothesis behind MINX is that flattening the curve keeps the follicular enzyme in its productive zone for roughly 10 to 12 hours instead of one hour, at the same total daily dose. Whether the curve change translates into measurably more hair in patients is the open question MINX is built to test.
The pericardial-effusion read. Pericardial effusion is the scariest cardiac risk attached to minoxidil. It is rare at hair-loss doses, but it is not zero-risk per FAERS (Gupta 2025 reported a statistically significant disproportionality signal at LDOM doses of 2.5 mg and below). The smoother delivery curve is hypothesized to blunt acute, peak-driven cardiovascular effects. Pericardial effusion is exposure-driven, not peak-driven. MINX delivers the same total minoxidil over the course of a day, so we would not expect, and we are not claiming, a difference on that endpoint.
The bottom line. A real prolonged-release oral minoxidil has to show a delayed peak, a low peak, and the same area under the curve as a standard dose. Sublingual at 5 mg does not show any of them. MINX is the only oral minoxidil with human PK data meeting all three.